Vivek Subbiah: Future of early-phase drug development and precision medicine is bright at Gustave Roussy Cancer Center!
Vivek Subbiah shared a post by Adrien Mouren, on X and added:
“Future of early-phase drug development and precision medicine is bright at Gustave Roussy Cancer Center!
Such a delight to meet with amazing colleagues Arnaud Bayle and Adrien Mouren at the Prism Center IHU kickoff event and discuss latest and greatest in drug development!
Thank you for all your insightful questions.”
Quoting Adrien Mouren’s post:
“Feeling inspired after Vivek Subbiah‘s insightful talk on precision medicine at the kick-off meeting for Prism Center in University of Paris-Saclay and Gustave Roussy Cancer Center.
His visionary approach is a model for us all in advancing cancer care through patient-centric clinical trials.”
Source: Vivek Subbiah/X and Adrien Mouren/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.
